@entity2067 prophylaxis prevents @entity21130 . The present review estimates the potential magnitude of this problem in less developed countries, assessing the need for prophylaxis, along with its cost-effectiveness and feasibility. Late @entity548 , occurring between 2 and 12 weeks, often leads to @entity204 or permanent disability. Its median incidence in developed countries is 7 per 100,000 births. Incidences in less developed countries may be much higher. Three incidence scenarios are proposed and the corresponding losses of disability-adjusted life-years (DALYs) calculated. Under the intermediate scenario, late @entity548 accounts for 0.1% to 0.2% of DALYs lost to @entity1 less than 5 years of age. Assuming a cost of +1.00 per injection, each DALY saved would cost +133. Decisions on prophylaxis must be made on a national basis, considering mortality levels and causes, health budgets, and feasibility. Comparison with the impact of diseases prevented by breast-feeding shows that concern with @entity548 should not affect breast-feeding promotion efforts, although strategies for supplementing breast-fed @entity1 must be explored.

XXXX prophylaxis in less developed countries: policy issues and relevance to breastfeeding promotion.

@entity1 :: ('9606', 'Species') :: ['children', 'infants'] @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhagic disease'] @entity2067 :: ('MESH:D014812', 'Chemical') :: ['Vitamin K'] @entity21130 :: ('MESH:D006475', 'Disease') :: ['hemorrhagic disease of the newborn'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death']
@entity2067 :: (MESH:D014812,Chemical) :: ['Vitamin K']
